Eli
Lilly’s Muvalaplin Shows Promising Results in Reducing Lipoprotein(a) Levels in Adults at High Risk for Cardiovascular Events
Muvalaplin, Lipoprotein(a) [Lp(a)], Cardiovascular risk, Oral drug, Phase II trial, Eli Lilly, Cholesterol reduction
Pharmaceutical Giants Eli Lilly and Novo Nordisk Face Challenges Despite Strong Sales Growth
Eli Lilly, Novo Nordisk, Q3 2024 financial results, Obesity drugs, Weight loss therapies, Pharmaceutical industry challenges, Market competition, Supply pressures, Pricing issues
Roche Advances Alzheimer’s Disease Diagnosis with Breakthrough Blood Test
Alzheimer’s disease, blood test, Roche, Eli Lilly, FDA breakthrough device designation, pTau217, amyloid pathology, early diagnosis.
Eli Lilly’s Stock Plummets Following Q3 Earnings Miss and Reduced Revenue Forecast
Eli Lilly, Q3 earnings, revenue forecast, stock drop, diabetes drugs, weight-loss drugs, obesity drug sales
Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients
Eli Lilly, Kisunla, Alzheimer’s disease, brain swelling, modified dosing regimen, ARIA-E risk reduction
Modified Dosing Regimen of Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Reduces Brain Swelling
Alzheimer’s disease, Eli Lilly, Kisunla (donanemab), Modified dosing regimen, ARIA-E (amyloid-related imaging abnormalities with oedema/effusion), Brain swelling, TRAILBLAZER-ALZ 6 Phase IIIb trial
Lilly and J&J Unveil Promising IL-23 Inhibitor Data for Crohn’s Disease, Setting Stage for FDA Decisions
Crohn’s disease, IL-23 inhibitors, Eli Lilly, Johnson & Johnson, Omvoh, Tremfya, clinical trials, FDA decisions.
NICE Rejects Alzheimer’s Drug Kisunla Despite UK Regulatory Approval
NICE, Alzheimer’s disease, donanemab, Kisunla, Eli Lilly, MHRA, NHS, cost-effectiveness
Eli Lilly Expands Global Innovation Reach with New Research Centers in China
Eli Lilly, China, Research Centers, Innovation, Gateway Labs, Biotechnology, Drug Development
Lilly’s Omvoh Outperforms J&J’s Stelara in Phase III Crohn’s Disease Trial
Omvoh (mirikizumab), Stelara (ustekinumab), Crohn’s disease, Phase III trial, Inflammatory bowel disease (IBD), Eli Lilly, Johnson & Johnson